CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial (CLOTBUST-HF)
|ClinicalTrials.gov Identifier: NCT01240356|
Recruitment Status : Completed
First Posted : November 15, 2010
Results First Posted : May 23, 2016
Last Update Posted : May 23, 2016
|Condition or disease||Intervention/treatment||Phase|
|Stroke||Device: 2-MHz transcranial Doppler ultrasound Device: 2-MHz transcranial Doppler ultrasound insonation||Phase 1 Phase 2|
Ultrasound energy to enhance intravenous rt-PA thrombolysis is a promising novel treatment modality for ischemic stroke. Despite encouraging safety data utilizing diagnostic frequencies of transcranial Doppler (TCD) ultrasound, lack of widespread availability of trained personnel has limited its application.
- The primary specific aim for this pilot phase I/II study is to assess the safety of a novel, external Hands-Free TCD ultrasound system. Safety of the new Hands-Free TCD system will first be assessed in healthy volunteers. Safety in these participants will be determined by detailed neurological and dermatological exams and MRI imaging of the brain. Next, safety of the device will be evaluated in two distinct sets of acute ischemic stroke patients: 0-3 hour patients treated with standard IV rt-PA and 3-6 hour non-lytic, image-selected patients treated with sonolysis (with or without intravenous microbubbles). Among the healthy volunteers the primary measures of safety will be to have no detectable changes in a detailed neurological exam nor any blood- brain barrier (BBB) disruption or changes in permeability. Among both the 0-3 hour and 3-6 hour groups the primary measure of safety will be to not tolerate greater than a 10% rate of symptomatic intracerebral hemorrhage (sICH) within 24 hours.
* The primary hypothesis is that replacing conventional TCD ultrasound hand-held TCD technology with a Hands-Free system will be safe in healthy volunteers as well as acute ischemic stroke patients.
If the device is found to be safe in either the 0-3 hour or 3-6 hour groups,
- the secondary aims for this study will explore the rates of arterial recanalization in the 0-3 hour and/or 3-6 hour groups, favorable outcomes, and clinical recovery. The secondary aims will assess the hypothesis is that Hands-Free TCD will display similar recanalization and early clinical recovery rates compared to available historical diagnostic TCD ultrasound controls exposed to conventional FDA-approved TCD technology.
Data generated during this phase I/II trial will evaluate the safety of replacing an operator-dependent TCD device with an operator-independent unit. In turn, this will allow extensive availability of therapeutic ultrasound and improve enrollment into ultrasound-enhanced thrombolysis stroke trials.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Combined Lysis of Thrombus in Brain Ischemia With Transcranial Ultrasound and Systemic T-PA-Hands-Free. A Phase I/II Pilot Safety Trial|
|Study Start Date :||December 2008|
|Primary Completion Date :||October 2013|
|Study Completion Date :||October 2013|
Experimental: Phase I: Healthy Volunteers
Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
Device: 2-MHz transcranial Doppler ultrasound
2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
Experimental: Phase II: 0-3 hour Patients
Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
Device: 2-MHz transcranial Doppler ultrasound insonation
2-hours of hands-free ultrasound delivered to in the intracranial vessels.
- Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain [ Time Frame: 2-3 hours after treatment ]Phase I : Imaging of the brain via MRI scans was performed to determine if the Hands-Free transcranial Doppler (TCD) system results in any BBB-disruption or deterioration in permeability.
- Safety in Phase II Group as Measured by Incidence of Symptomatic Intracerebral Hemorrhage [ Time Frame: within 24 hours ]Phase II: Determine if the Hands-Free TCD will not result in higher than 10% rate of symptomatic intracerebral hemorrhage (ICH) within 24 hours (defined as clinical worsening > 4 NIH Stroke Scale (NIHSS) points and presence of hemorrhage on CT scan that in the opinion of the treating physician is causatively related to ICH on CT) in 0-3 hours acute stroke patients treated with intravenous tissue-type plasminogen activator (IV-t-PA).
- Number of Participants in Phase I Group With Neurological Deterioration as Measured by Neurological Examination [ Time Frame: 2-3 hours after treatment ]The neurological examinations comprised assessments of mental status and orientation, cranial nerve examination, muscle strength and tone, deep tendon reflexes, sensory testing, coordination, and gait.
- Number of Participants in Phase I Group With Adverse Events During and After Study Treatment With HF TCD [ Time Frame: 2-3 hours after treatment ]Phase I - A group of healthy volunteers will be assessed to determine the feasibility and activity of hands-free (HF) transcranial Doppler (TCD). Adverse events include subject complaints regarding discomfort of the device and dermatological adverse events as evidenced by a detailed physical examination of skin integrity post-insonation.
- Percentage of Participants in the Phase II Group That Show Arterial Recanalization as Measured Using Standard Transcranial Doppler Ultrasound Systems [ Time Frame: 2-3 hours after treatment ]Ischemic stroke patients: 2-hour rates of arterial complete and partial recanalization as measured using standard Transcranial Doppler Ultrasound systems.
- Percentage of Participants in Phase II Group With Neurological Worsening as Determined by the NIH Stroke Scale [ Time Frame: within 90 days of enrollment ]The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. Each item on the NIHSS scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
- Percentage of Participants in Phase II Group With Excellent Outcome as Measured by Modified Rankin Scale (mRS) [ Time Frame: at 3-months from enrollment ]A modified Rankin Scale (mRS) score of 0 or 1 indicates an excellent outcome. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS scale ranks patients from 0 to 6 (0 is the best score, 6 is the worst score).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01240356
|United States, Alabama|
|University of Alabama Birmingham|
|Birmingham, Alabama, United States, 35233|
|United States, Texas|
|UT Medical School-Houston|
|Houston, Texas, United States, 77030|
|Principal Investigator:||James C. Grotta, MD||UT Medical School-Houston|